T3 *DOES NOT* need to be used with HGH.

[poantrex]

Okay, i'm seeing everyone recommend the use of cytomel concurrently with growth hormone , and i'm sick of it. This belief stems from the fact that there are a few studies indicating that exogenous HGH impairs the production of _T4_, and somehow bodybuilders misinterpreted that.

T4 is not very metabolically active, whereas T3 is.

HGH actually _increases_ the conversion of T4 to T3, and Free t3 levels are signifigantly higher when running HGH - if you add T3 to a HGH cycle you may be negating that benefit. Here are some studies to prove it:


Effects of recombinant growth hormone therapy on thyroid hormone concentrations.

Kalina-Faska B, Kalina M, Koehler B.

Department of Pediatric Endocrinology and Diabetes, Medical University of Silesia, Katowice, Poland. [email protected]

BACKGROUND AND OBJECTIVE: There are numerous, often contradictory reports on the effects of growth hormone (GH) therapy on thyroid function. The aim of this study was to assess the effect of such therapy on serum concentrations of thyroid hormones in GH-deficient children euthyroid prior to the treatment, and to determine the necessity of thyroid hormone administration in these patients. MATERIAL AND METHODS: The study included 32 GH-deficient patients in the first stage of sexual development, in whom disorders of thyroid function could be excluded. The inclusion criteria were based on clinical examination and levels of thyroxine (T4), triiodothyronine (T3), free thyroxine (fT4), free triiodothyronine (fT3), reverse triiodothyronine (rT3), thyrotropin (TSH) before and after stimulation with thyrotropin-releasing hormone (TRH). Recombinant growth hormone (rGH) (Genotropin 16U, Pharmacia) was administered at a dose of 0.7 U/kg/week. Fasting blood samples were drawn before treatment and after 3, 6, 9 and 12 months of therapy. Thyroid hormones were measured using RIA and IRMA methods. RESULTS: There were no physical signs of hypothyroidism in the patients examined during 12 months of rGH administration, and the satisfactory growth rate was achieved. T4 levels decreased in the first 3 months but remained within the normal range, and then returned to the values prior to the treatment. A similar trend was observed for fF4, with 28.5% of patients exhibiting fF4 levels below the normal in the 3rd month. An increase during the first 3 months of therapy was observed in the cases of T3 (statistically non-significant) and fT3, and these values then fell to levels within the normal range of patients' age. During treatment, TSH levels decreased but remained within the normal range. CONCLUSIONS: A transient decrease in T4 concentrations in the 3rd month with unchanged T3 and an increase in fT3 concentrations probably result from the effect of rGH on the peripheral metabolism of thyroid hormones. The results obtained do not support the use of thyroid hormone therapy with levothyroxine during the first year of rGH therapy in patients who are initially euthyroid.

PMID: 14756384 [PubMed - indexed for MEDLINE]

Effects of short-term growth hormone treatment on PTH, calcitriol, thyroid hormones, insulin and glucagon.

Brixen K, Nielsen HK, Bouillon R, Flyvbjerg A, Mosekilde L.

University Department of Endocrinology and Metabolism, Aarhus County Hospital, Denmark.

We measured changes in serum insulin-like growth factor-1 (IGF-1), calcitriol, parathyroid hormone (PTH), thyroid hormones, insulin, and plasma glucagon in response to seven days of treatment with a pharmacological dosage of recombinant human growth hormone (r-hGH) (0.1 IU/kg sc twice daily) or placebo in 20 normal male volunteers to evaluate whether the effect of r-hGH on biochemical bone markers could be attributed to changes in these hormones. Serum IGF-1 (p < 0.001) and vitamin D-binding protein (p < 0.001) increased steadily during treatment returning to baseline at day 14. Total calcitriol (p < 0.01) and free calcitriol index (p < 0.001) increased transiently at day 4. Furthermore, serum insulin (p < 0.001) and both total (p < 0.001) and free triiodothyronine (p < 0.02) increased during treatment, while serum PTH and plasma glucagon remained unchanged. In conclusion, pharmacological doses of r-hGH increased not only IGF-1 but also free-calcitriol index, insulin, and free T3. The increase in these hormones may be co-responsible for some of the observed effects of r-hGH on bone turnover and calcium homeostasis.

Publication Types:

* Clinical Trial
* Controlled Clinical Trial


PMID: 1449044 [PubMed - indexed for MEDLINE]

[poantrex]

Bump

[poantrex]

TTT f

[poantrex]

bump

[MIKE_XXL]

Good post Bro! But i will still use 12.5mcg ED

[mrtosa]

what does gear and the other vet think of this threath?

[Gear]

I have always suggested the use of T4 when using HGH since HGH will effect your T4. This thread is very old, please let's not bump these threads.

Thank you.

-Gear